Improvement Effect Of Bifidobacterium In Patients Receiving Resection Of Colorectal Polyps

Purpose:Postoperative symptoms,intestinal dysfunction and recurrence are common problems after colorectal polypectomy.We aimed to evaluate the efficacy of Bifidobacterium in postoperative patients.Method:In this single-center,randomized,double-blind,placebo-controlled trial,adults(>18 years)undergoing endoscopic resection of colorectal polyps received either probiotics(Bifidobacterium animalis subsp.lactis MH-02,2 × 109 colony-forming units per packet)or placebo treatment once daily for 7 days.The primary clinical endpoint was improvement in symptoms(defined as the difference in mean total postoperative symptom scores between the two groups)within 7 days postoperatively.Secondary clinical endpoints were single symptom scores,time to recovery of bowel function,and changes in the gut microbiota.The registration number for this study is Chi CTR2100046687.Results:A total of 100 individuals were enrolled(48 in the probiotic group and 52 in the placebo group).There was no difference in the mean score between the two groups(0.29 vs.0.43,P = 0.246).Colonic polyp size(P = 0.008)and preoperative symptoms(P = 0.032)were influential factors for the primary endpoint.In addition,MH-02 relieved defecation difficulties(P = 0.045)and shortened the time to recovery of bowel function(P = 0.032).High-throughput analysis showed that MH-02 could help restore intestinal microbiota diversity and increase the relative abundance of Bifidobacterium,Roseburia,Gemmiger,Blautia and Ruminococcus,while decreasing the relative abundance of Clostridium at the genus level(P < 0.05).Conclusion:In this prospective trial,MH-02 showed efficacy in patients undergoing resection of colorectal polyps,particularly in recovery of intestinal function,and the change in intestinal microbiota may provide evidence for further exploration of its therapeutic mechanisms.